480 related articles for article (PubMed ID: 30097670)
1. Influence of lanreotide on uptake of
Aalbersberg EA; de Wit-van der Veen BJ; Versleijen MWJ; Saveur LJ; Valk GD; Tesselaar MET; Stokkel MPM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Somatostatin Analog Therapy Differentially Alters
Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
7. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
9. The effect of long-acting somatostatin analogues on the uptake of [
Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours.
Coura-Filho GB; Hoff AAFO; Duarte PS; Buchpiguel CA; Josefsson A; Hobbs RF; Sgouros G; Sapienza MT
Nucl Med Commun; 2019 Sep; 40(9):920-926. PubMed ID: 31343614
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
15. Changes in biodistribution on
Cherk MH; Kong G; Hicks RJ; Hofman MS
Cancer Imaging; 2018 Jan; 18(1):3. PubMed ID: 29361984
[TBL] [Abstract][Full Text] [Related]
16. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
17.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
18. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
19. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
[No Abstract] [Full Text] [Related]
20.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
